Welcome to our dedicated page for Generation Bio Co. news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio Co. stock.
Generation Bio Co. (NASDAQ: GBIO) is a Cambridge, Massachusetts-based biotechnology company that reports focusing on T cell-driven autoimmune diseases using genetic medicine approaches. Its news flow provides insight into the progress of its cell-targeted lipid nanoparticle (ctLNP) platform, siRNA programs, corporate strategy and capital markets activity.
Company press releases highlight research updates on its ctLNP system, including non-human primate data showing selective delivery of siRNA to T cells and knockdown of specific molecular targets. News items also describe the development of lead siRNA candidates aimed at upstream regulators of T cell activation, proliferation and differentiation, reflecting the company’s emphasis on modulating autoreactive T cells in vivo.
Investors and followers of GBIO can also find regular financial results coverage, where Generation Bio reports quarterly cash balances, research and development spending, general and administrative expenses and net loss figures. These updates often include commentary on strategic priorities, cash runway expectations and one-time items such as lease-related settlements.
In addition to scientific and financial updates, Generation Bio’s news includes corporate and strategic developments. During 2025, the company announced a review of strategic alternatives, a significant restructuring of its workforce, leadership transitions in the chief executive role and a 1-for-10 reverse stock split intended to support continued Nasdaq listing. Later in the year, the company disclosed an Agreement and Plan of Merger with XOMA Royalty Corporation involving a tender offer and planned merger.
This news page aggregates these disclosures, allowing readers to follow Generation Bio’s research progress, strategic decisions and transaction-related announcements over time.
Generation Bio (Nasdaq: GBIO) announced the appointment of Dannielle Appelhans to its Board of Directors on July 18, 2022. Appelhans, currently COO of Rubius Therapeutics, brings extensive experience in pharmaceutical strategy and operations, including leadership roles at Novartis. Her expertise is expected to aid Generation Bio as it transitions from research to commercialization. Appelhans expressed enthusiasm about contributing to the company's mission of developing novel genetic medicines for rare diseases.
Generation Bio (Nasdaq: GBIO) is revising its GMP manufacturing strategy to optimize efficiency through enhanced rapid enzymatic synthesis (RES) of closed-ended DNA (ceDNA). The company will sublease its planned GMP facility and adopt a smaller, flexible manufacturing footprint, extending its cash runway into 2025. This shift will not affect production timelines for its ongoing liver, retina, and vaccine programs. The RES process allows for high purity and scalability, enabling the company to produce millions of doses with shorter production cycles.
Generation Bio (Nasdaq: GBIO) will have CEO Geoff McDonough participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 10th at 11:00 a.m. ET in New York. A live webcast of the event will be accessible on the investor section of the company's website, with a replay available for 30 days afterwards.
The company focuses on innovative genetic medicines for rare and prevalent diseases using a unique DNA construct and delivery system aimed at providing durable treatments.
Generation Bio Co. (Nasdaq: GBIO) reported steady progress in optimizing cell-targeted lipid nanoparticles (ctLNPs) for genetic medicines in liver and retina applications, as well as vaccine development. The company maintains a strong cash position of $337.0 million, projected to fund operations into 2024. In Q1 2022, R&D expenses rose to $25.6 million, while G&A expenses increased to $9.8 million, resulting in a net loss of $35.0 million, or $0.61 per share, compared to a net loss of $25.6 million a year earlier.
Generation Bio Co. (Nasdaq: GBIO) announced that its CEO, Geoff McDonough, will participate in the 21st Annual Needham Virtual Healthcare Conference on April 11th at 11:00 a.m. ET. A live webcast of the event will be available on the company’s investor website, with a replay accessible for 30 days post-event. Generation Bio focuses on developing innovative genetic medicines for rare and prevalent diseases, utilizing its proprietary non-viral genetic medicine platform, which includes unique delivery systems and manufacturing processes aimed at providing durable and scalable treatments.
Generation Bio Co. (Nasdaq: GBIO) announced that its CEO, Geoff McDonough, will participate in the Gene Therapy panel at the 42nd Annual Cowen Health Care Conference on March 9 at 12:50 p.m. ET. A live webcast will be available on the investor section of the company's website, with a replay accessible for 30 days following the event.
The company is focused on innovative genetic medicines aimed at providing durable treatments for rare and prevalent diseases, utilizing its proprietary non-viral genetic medicine platform.
Generation Bio Co (Nasdaq: GBIO) reported a cash position of $375.1 million at the end of 2021, expected to fund operations through 2024. The company is focused on advancing its genetic medicine platform, targeting liver diseases and retinal conditions. In 2021, R&D expenses rose to $85.2 million from $58.5 million in 2020. The net loss for 2021 was $119.2 million, a decrease in loss per share from $2.95 to $2.12. The company aims to optimize its delivery systems for ongoing hemophilia A and Stargardt disease programs.
Generation Bio Co. (Nasdaq: GBIO) announced the promotion of Antoinette Paone to chief operating officer (COO). Having previously served as senior vice president and head of regulatory affairs since 2018, she brings over 20 years of experience in the pharmaceutical and biotech sectors. Paone will oversee the company's good manufacturing practice (GMP) capabilities, vital for developing its unique genetic medicine platform, which includes closed-ended DNA constructs and a lipid nanoparticle delivery system. This strategic move is aimed at enhancing operational efficiency and supporting the company's mission to deliver innovative treatments.
Generation Bio Co. (Nasdaq: GBIO) announced its participation in the virtual 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2022, from 8:15-8:55 a.m. ET. A live webcast of the presentation and Q&A will be accessible on the company's investor website, with a replay available for 30 days post-event. Generation Bio focuses on innovative genetic medicines aimed at treating rare and prevalent diseases, utilizing a novel delivery system and scalable manufacturing process to enhance treatment durability and efficiency.
Generation Bio (Nasdaq: GBIO) reported significant advancements in its genetic medicine platform for treating hemophilia A, demonstrating up to 205% normal human factor VIII expression in mouse studies using its closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticle (ctLNP) technology. Non-human primate studies showed up to 2% factor VIII expression, with noted variability. The company plans to enhance species translation for further development. Upcoming updates and timing for its first IND submission are expected in 2022.